Fox Chase Cancer Center News

PHILADELPHIA (May 29, 2020)— The study ultimately concluded that treatment with dinutuximab plus irinotecan was not superior to the established second-line treatment for relapsed/refractory small cell lung cancer.

PHILADELPHIA (May 29, 2020) — After earlier research found that the same lymphocytes that can treat a tumor are also present in bone marrow, Fox Chase became one of the first institutions to open a trial investigating the effectiveness of using marrow infiltrating lymphocytes for the treatment of NSCLC.

PHILADELPHIA (May 29, 2020)—Pembrolizumab (Keytruda) in combination with axitinib (Inlyta) continues to show improved efficacy in the treatment of advanced renal cell carcinoma when compared with the use of sunitinib (Sutent).

PHILADELPHIA (May 28, 2020)—Breast cancer patients describe having thoughts and feelings that can prevent them from discussing cancer-related sexual issues with their healthcare providers, even if they would like to.

PHILADELPHIA (May 20, 2020) — According to the 2019 national survey, 48.7 percent of oncology physician assistants reported burnout, as opposed to 34.8 percent in 2015.

PHILADELPHIA (May 18, 2020)—Fox Chase was recognized for its use of the Monarch Platform, a technology that features a familiar controller-like interface that physicians use to navigate a flexible robotic endoscope to the periphery of the lung. The technology improves reach, vision, and control.

PHILADELPHIA (May 14, 2020) – May is Skin Cancer Prevention Month.  The two most common types of skin cancers, basal cell and squamous cell skin cancers, are usually very treatable and most commonly found in areas exposed to the sun.

PHILADELPHIA (May 11, 2020) — Combination strategies targeting the immune checkpoint pathway from multiple angles may be the key. A recent study suggested the benefit of two immune checkpoint drugs, which showed promising response in this rare cancer.